Home Primary Antibodies TIPE2 Antibody [A15H13]

research use only

TIPE2 Antibody [A15H13]

Cat.No.: F7513

    Application: Reactivity:
    • F7513-wb
      Lane 1: THP-1

    Usage Information

    Dilution
    1:1000
    1:30
    1:100
    1:50
    Application
    WB, IP, IHC, IF
    Reactivity
    Human
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    20 kDa 18 kDa, 36 kDa
    *Why do the predicted and actual molecular weights differ?
    The following reasons may explain differences between the predicted and actual protein molecular weight.
    Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

    Datasheet & SDS

    Biological Description

    Specificity
    TIPE2 Antibody [A15H13] detects endogenous levels of total TIPE2 protein.
    Clone
    A15H13
    Synonym(s)
    Tumor necrosis factor alpha-induced protein 8-like protein 2; TIPE2; TNF alpha-induced protein 8-like protein 2; TNFAIP8-like protein 2; Inflammation factor protein 20; TNFAIP8L2
    Background
    TNF‑α–induced protein 8–like 2 (TIPE2; TNFAIP8L2) is a cytosolic immune‑regulatory protein of the TNFAIP8/TIPE family that functions as a negative modulator of innate and adaptive immune signaling in myeloid and lymphoid cells. The protein is constitutively expressed in macrophages, NK cells, and T lymphocytes and does not form a stable, pre‑assembled complex but instead engages membrane‑proximal and signaling‑adapter molecules to restrain NF‑κB and MAPK pathway activation. TIPE2 interacts with and dampens the activity of key kinases and adaptors in these cascades, including components that regulate IKK and JNK, thereby limiting the production of pro‑inflammatory cytokines and preventing excessive immune activation under homeostatic and challenge conditions. Reduced TIPE2 expression or loss‑of‑function exacerbates inflammatory pathology, as seen in models of colitis and arthritis, whereas forced overexpression of TIPE2 suppresses inflammatory signaling and ameliorates tissue damage, acting as a checkpoint in immune‑mediated diseases. TIPE2 exerts a dual, context‑dependent function, inhibiting antitumor immunity in some solid‑tumor microenvironments by enhancing immunosuppressive cell populations and dampening cytotoxic responses, yet in certain colitis‑associated cancer models, it can act as a colonocyte‑intrinsic tumor suppressor by restraining inflammation‑driven proliferation.
    References
    • https://pubmed.ncbi.nlm.nih.gov/31616442/
    • https://pubmed.ncbi.nlm.nih.gov/38377476/

    Tech Support

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3

    If you have any other enquiries, please leave a message.